These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 23909034)

  • 21. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
    Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
    Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
    Shien T; Shimizu C; Seki K; Shibata T; Hojo T; Ando M; Kohno T; Katsumata N; Akashi-Tanaka S; Kinoshita T; Fujiwara Y
    Breast Cancer Res Treat; 2009 Jan; 113(2):307-13. PubMed ID: 18286370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
    Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
    Timovska YO; Pivnyuk VM; Oliynichenko GP; Anikushko MF; Zachartseva LM; Chekhun VF
    Exp Oncol; 2009 Dec; 31(4):231-6. PubMed ID: 20010529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
    Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
    Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
    Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
    Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
    Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.